GO
Loading...

Amgen Inc

More

  • Final Glance: Biotechnology companies Thursday, 24 Jul 2014 | 6:22 PM ET

    Amgen Inc. rose$. 25 or. 2 percent, to $122.26. Biogen Idec fell$. 81 or. 2 percent, to $336.79. Celgene Corp. fell $2.93 or 3.3 percent, to $86.19.

  • FDA reviewing what could be first biosimilar drug Thursday, 24 Jul 2014 | 3:41 PM ET

    Nearly five years after Congress passed a law enabling future approval of biosimilars, for the first time the FDA has accepted an application to sell a similar, but not identical, version of a biologic drug.

  • Midday Glance: Biotechnology companies Thursday, 24 Jul 2014 | 1:23 PM ET

    Biogen Idec fell$. 94 or. 3 percent, to $336.66. Celgene Corp. fell $3.22 or 3.6 percent, to $85.90. Gilead Sciences Inc. rose$. 04 or percent, to $90.38.

  • Early Glance: Biotechnology companies Thursday, 24 Jul 2014 | 11:37 AM ET

    Amgen Inc. fell$. 51 or. 4 percent, to $121.50. Biogen Idec rose$. 29 or. 1 percent, to $337.89. Celgene Corp. fell $3.63 or 4.1 percent, to $85.49.

  • Final Glance: Biotechnology companies Tuesday, 22 Jul 2014 | 6:02 PM ET

    Amgen Inc. rose $2.08 or 1.7 percent, to $121.11. Biogen Idec rose $1.17 or. 4 percent, to $303.67. Celgene Corp. rose $1.35 or 1.6 percent, to $86.66.

  • Midday Glance: Biotechnology companies Tuesday, 22 Jul 2014 | 1:57 PM ET

    Amgen Inc. rose $1.68 or 1.4 percent, to $120.71. Biogen Idec rose $2.64 or. 9 percent, to $305.14. Celgene Corp. rose $1.30 or 1.5 percent, to $86.61.

  • Early Glance: Biotechnology companies Tuesday, 22 Jul 2014 | 11:16 AM ET

    Amgen Inc. rose $1.30 or 1.1 percent, to $120.33. Biogen Idec rose $5.25 or 1.7 percent, to $307.75. Celgene Corp. rose $1.69 or 2.0 percent, to $87.00.

  • Midday Glance: Biotechnology companies Wednesday, 16 Jul 2014 | 2:54 PM ET

    Amgen Inc. rose$. 05 or percent, to $116.91. Biogen Idec fell $6.64 or 2.1 percent, to $305.36. Celgene Corp. fell$. 70 or. 8 percent, to $86.08.

  • Early Glance: Biotechnology companies Wednesday, 16 Jul 2014 | 11:11 AM ET

    Amgen Inc. rose$. 29 or. 3 percent, to $117.16. Biogen Idec fell $4.28 or 1.4 percent, to $307.72. Celgene Corp. rose$. 21 or. 2 percent, to $86.99.

  • In 2012, Ernst& Young voluntarily decided to cease performing lobbying work for SEC registrant audit clients. " "Auditor independence is critical to the integrity of the financial reporting process," said Scott Friestad, an associate director in the SEC's enforcement division.

  • July 2- Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc to develop targeted cancer therapy due to unsatisfactory results.

  • *Shire rejects AbbVie offer valued at 46.26 pounds a share. LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into lower tax rates abroad via an acquisition.

  • LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into the London- listed group's low tax rate. Abbvie's takeover offer proposed creating a new U.S.-listed holding company with a UK tax domicile in a so-called "inversion" move.

  • *Shire expecting to receive approaches, taps Citi- sources. LONDON, June 17- Shares in Shire hit a record high on Tuesday on expectations of a takeover as dealmaking sweeps the drugs sector, after Reuters reported the group had hired investment bank Citi as a defence adviser. Shire and Citi declined to comment.

  • Shire braces for takeover bids, hires Citi: Sources Monday, 16 Jun 2014 | 2:25 PM ET
    Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc.

    Shire has hired investment bank Citi as an adviser following a wave of deals in the healthcare sector.

  • LONDON, June 16- London- listed drugmaker Shire has hired investment bank Citi as an adviser, expecting to receive takeover approaches following a wave of deals in the healthcare sector, sources familiar with the matter told Reuters.

  • CHICAGO, June 6- A new way of evaluating tumors may soon help cancer patients identify the underlying genetic link to their disease- and the best possible treatment- all in a single test. "We really are moving away from this one drug, one biomarker, one companion diagnostic," said Dr Richard Pazdur, the U.S. Food and Drug Administration's oncology chief.

  • Early movers: HSH, PPC, AAPL, GM & more Tuesday, 27 May 2014 | 7:38 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • FRANKFURT, May 23- U.S. health regulators on Friday approved Qiagen NV's gene-testing kit to identify those colorectal cancer patients most likely to benefit from Amgen Inc's drug, Vectibix, Qiagen said.

  • May 23- For two months last summer, Stanford Law School professor Joseph Grundfest locked himself away in his home office in California's Portola Valley.